Abstract: A linker peptide for constructing a fusion protein. The linker peptide comprises a flexible peptide and a rigid peptide. The flexible peptide consists of one or more flexible units. The rigid peptide consists of one or more rigid units. The flexible unit comprises two or more amino acid residues selected from Gly, Ser, Ala, and Thr. The rigid unit comprises a human chorionic gonadotropin ?-subunit carboxy-terminal peptide (CTP) bearing a plurality of glycosylation sites. The linker peptide can more effectively eliminate mutual steric hindrance of two fusion molecules, decreasing a reduction/loss of polymerization or activity resulting from improper folding of an active protein or a conformational change. On the other hand, the negatively charged, highly sialylated CTP can resist renal clearance, further prolonging a half-life of a fused molecule and enhancing bioavailability of a fused protein.

Abstract: The present invention relates to a medicine for treating disorders of glucose and/or lipid metabolism. This invention demonstrates a new therapeutic target for treatment of glucose and/or lipid metabolic disorders. The invention further provides a method of treating glucose and/or lipid metabolic disorders, administering to a subject comprising a Nogo-B inhibitor, thereby treating the glucose and/or lipid metabolic disorders.

Abstract: The present invention relates to a medicine for treating disorders of glucose and/or lipid metabolism. This invention demonstrates a new therapeutic target for treatment of glucose and/or lipid metabolic disorders. The invention further provides a method of treating glucose and/or lipid metabolic disorders, administering to a subject comprising a Nogo-B inhibitor, thereby treating the glucose and/or lipid metabolic disorders.